Maurílio De Souza Cazarim
Biographic Data
| ID | 1790657 |
|---|---|
| NAME | Maurílio De Souza Cazarim |
| GIVEN NAMES | Maurílio De Souza |
| FAMILY NAME | Cazarim |
| SIGNATURE | CAZARIM M S |
| AFFILIATIONS | Universidade de São Paulo |
| ORCID | 0000-0002-2826-5903 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital
OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital. METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and …
Cost-effectiveness analysis is a mandatory strategy for health systems
Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporat…
No prominent works on this page.
Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital
OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital. METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and …
Cost-effectiveness analysis is a mandatory strategy for health systems
Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporat…
Internal Medicine (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Average cost (1 work) · Boceprevir (1 work) · Clinical pharmacy (1 work) · Cost analysis (1 work) · Cost effectiveness (1 work) · Cost-effectiveness analysis (1 work) · Emergency Medicine (1 work)